CD109 Overview
Molecule Name
DNA polymerase alpha subunit
Synonyms
CD109,CPAMD7,r150,p180,CPAMD7
Drug Development Progress
Drugs in Clinical Trials3
Approved Drugs2
Highest Development StageApproved
Target Synonym
P180，N Syndrome (Mental Retardation， Malformations， Chromosome Breakage)，NSX，VEODS，Polymerase (DNA Directed)， Alpha，POLA1，Polymerase (DNA-Directed)， Alpha (70kD)，DNA Polymerase Alpha 1， Catalytic Subunit，POLA，EC:2.7.7.7，EC 2.7.7.7，DNA Polymerase Alpha Catalytic Subunit，DNA Polymerase Alpha Catalytic Subunit P180，Polymerase (DNA) Alpha 1， Catalytic Subunit，DNA Polymerase I，Polymerase (DNA Directed)， Alpha 1， Catalytic Subunit
Background
CD109 is a glycosyl phosphatidylinositol (GPI)-linked glycoprotein that localizes to the surface of platelets, activated T-cells, and endothelial cells. CD109 is expressed in many malignant tumors, including various squamous cell carcinomas and adenocarcinomas, and plays a role as a multifunctional coreceptor.CD109 reportedly associates with transforming growth factor (TGF)-β receptors and negatively regulates TGF-β signaling in keratinocytes. Additionally, CD109 is potentially related to signal transducer and activator of transcription-3 signaling and aberrant cell proliferation.
CD109 Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Clofarabine (Boyen) | BY-101 | Phase 3 Clinical | Boyen Therapeutics Inc | Leukemia, Myeloid, Acute | Details |
| Alkasar-18 | NOAC; Alkasar-18; N4-octadecyl-ara-C | Phase 1 Clinical | University of Zurich | Cerebral Hemorrhage; Neoplasms; Atrial Fibrillation | Details |
| Sapacitabine | CS-682; CYC-682 | Phase 1 Clinical | Daiichi Sankyo Co Ltd | Leukemia; Myelodysplastic Syndromes; Breast Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, T-Cell, Cutaneous; Carcinoma, Non-Small-Cell Lung | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Clofarabine | CAFdA; JC0707; GZ-393590; SAR-393590; 2-Cl-2-F-araA | Approved | Genzyme Corp | Clolar, Evoltra, Ivozall, Clofarex | United States | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Genzyme Corp | 2004-12-28 | Neoplasms; Angioimmunoblastic T-cell Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Waldenstrom Macroglobulinemia; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Lymphoma; Lymphoproliferative Disorders; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Histiocytosis, Langerhans-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Multiple Myeloma; Leukemia; Lymphoma, Large B-Cell, Diffuse; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Leukemia, Lymphoid; Intestinal Neoplasms; Lymphoma, T-Cell, Peripheral; Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Hematologic Neoplasms; Leukemia, Myeloid; Leukemia, Myelogenous, Chronic; Solid tumours | Details |
| Nelarabine | 506U; 506-U78; GW-506U; GW-506U78; GI-262250X; NSC-686673 | Approved | Novartis Pharma Ag, Glaxosmithkline Plc | Arranon, ArranonG, Atriance | United States | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Sandoz | 2005-10-28 | Sezary Syndrome; Mycosis Fungoides; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, T-Cell; Angioimmunoblastic T-cell Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell, Cutaneous; Waldenstrom Macroglobulinemia; Lymphoma, T-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Multiple Myeloma; Leukemia-Lymphoma, Adult T-Cell; Myeloproliferative Disorders; Myelodysplastic Syndromes; Plasmacytoma; Lymphoma, B-Cell, Marginal Zone | Details |